Three models combining an imaging parameter with clinical factors as potential prognostic variables of overall survival in patients with gliomas
| Factors | HR (95% CI) | P Value |
|---|---|---|
| Model 1 | ||
| Age older than 50 yr | 1.03 (0.99–1.06) | .17 |
| Biopsy vs resection | 4.11 (1.68–10.05) | .002 |
| Grade 3 vs 2 | 1.20 (0.19–7.65) | .85 |
| Grade 4 vs 2 | 1.21 (0.28–5.33) | .80 |
| Karnofsky score < 80 | 2.56 (1.19–5.51) | .02 |
| Ktrans ≥ 0.05 min−1 | 4.53 (1.22–16.82) | .02 |
| Model 2 | ||
| Age older than 50 yr | 1.06 (1.03–1.09) | .0002 |
| Biopsy vs resection | 3.68 (1.54–8.78) | .004 |
| Grade 3 vs 2 | 1.06 (0.16–6.89) | .95 |
| Grade 4 vs 2 | 1.76 (0.35–8.75) | .49 |
| Karnofsky score < 80 | 3.21 (1.48–6.92) | .003 |
| Vp ≥ 5 mL/100 g | 1.30 (0.37–4.54) | .68 |
| Model 3 | ||
| Age older than 50 yr | 1.03 (0.99–1.07) | .087 |
| Biopsy vs resection | 4.36 (1.77–10.77) | .002 |
| Grade 3 vs 2 | 1.28 (0.20–8.25) | .79 |
| Grade 4 vs 2 | 1.00 (0.22–4.63) | .99 |
| Karnofsky score < 80 | 2.51 (1.16–5.43) | .02 |
| Marked contrast enhancement | 4.79 (1.22–18.87) | .03 |